Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.
Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory of Cancer Research, Frederick, Maryland 21702-1201, United States.
J Nat Prod. 2022 Jun 24;85(6):1603-1616. doi: 10.1021/acs.jnatprod.2c00240. Epub 2022 Jun 13.
Seven new peptaibols named tolypocladamides A-G have been isolated from an extract of the fungus , which inhibits the interaction between Raf and oncogenic Ras in a cell-based high-throughput screening assay. Each peptaibol contains 11 amino acid residues, an octanoyl or decanoyl fatty acid chain at the N-terminus, and a leucinol moiety at the C-terminus. The peptaibol sequences were elucidated on the basis of 2D NMR and mass spectral fragmentation analyses. Amino acid configurations were determined by advanced Marfey's analyses. Tolypocladamides A-G caused significant inhibition of Ras/Raf interactions with IC values ranging from 0.5 to 5.0 μM in a nanobioluminescence resonance energy transfer (NanoBRET) assay; however, no interactions were observed in a surface plasmon resonance assay for binding of the compounds to wild type or G12D mutant Ras constructs or to the Ras binding domain of Raf. NCI 60 cell line testing was also conducted, and little panel selectivity was observed.
从一种真菌的提取物中分离得到了 7 种新的缩肽,命名为托利菌素 A-G,它们在基于细胞的高通量筛选测定中抑制 Raf 和致癌 Ras 之间的相互作用。每个缩肽含有 11 个氨基酸残基、N 端的辛酰基或癸酰基脂肪酸链和 C 端的亮氨醇部分。根据二维 NMR 和质谱碎裂分析阐明了缩肽序列。通过先进的 Marfey 分析确定了氨基酸构型。托利菌素 A-G 在纳米生物发光共振能量转移(NanoBRET)测定中对 Ras/Raf 相互作用具有显著的抑制作用,IC 值范围为 0.5 至 5.0 μM;然而,在表面等离子共振测定中,没有观察到化合物与野生型或 G12D 突变 Ras 构建体或 Raf 的 Ras 结合域的结合。还进行了 NCI 60 细胞系测试,观察到很少的面板选择性。